Ryan Logue
Pulmonary Disease · Indianapolis, INNPI 1093178477
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.7%), food and beverage and education — rather than concentrated in one kind of arrangement. GSK accounts for 64.5% of it on its own, with 33 other manufacturers making up the rest. 2025 is the largest year on record at $21,014, more than ten times the $73 reported in 2019. Among pulmonary disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 552 payments — averaging $54.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$19K
- AstraZeneca$2K
- Sanofi$1K
- Boehringer Ingelheim$947
- Regeneron Healthcare Solutions, Inc.$841
- Actelion Pharmaceuticals US, Inc.$699
- plus $5K from 28 others
What the payments were for
- Speaking & faculty fees$16,90057%
- Travel & lodging$1440%
- Food & beverage$12,28241%
- Education$4702%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 107 | $19,254 |
| AstraZeneca | 89 | $2,283 |
| Sanofi | 51 | $1,341 |
| Boehringer Ingelheim | 42 | $947 |
| Regeneron Healthcare Solutions, Inc. | 34 | $841 |
| Actelion Pharmaceuticals US, Inc. | 27 | $699 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $650 |
| Grifols USA, LLC | 21 | $451 |
| Insmed, Inc. | 18 | $318 |
| United Therapeutics Corporation | 13 | $312 |
| Amgen | 14 | $297 |
| AbbVie | 11 | $287 |
| Mallinckrodt Hospital Products Inc. | 10 | $233 |
| Johnson & Johnson | 13 | $206 |
| Medical Device Business Services, Inc. | 3 | $199 |
| Mylan Specialty L.p. | 12 | $193 |
| Inari Medical, Inc. | 1 | $178 |
| Philips North America LLC | 9 | $157 |
| Gilead | 7 | $145 |
| Viatris Specialty LLC | 5 | $109 |
| Verona Pharma, Inc. | 5 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Inogen, Inc. | 5 | $93 |
| Novartis | 5 | $88 |
| Merck | 4 | $69 |
| Advanced Respiratory, Inc | 2 | $69 |
| Bayer | 3 | $58 |
| Astellas Pharma US Inc | 2 | $44 |
| Pfizer | 2 | $37 |
| Pulmonx Corporation | 2 | $37 |
| La Jolla Pharmaceutical Company | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Electromed, Inc. | 2 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$17,594
- TEZSPIRE$370
- DUPIXENT$369
- FLOWTRIEVER CATHETER, S$178
- CT THROMBECTOMY SYSTEM KIT$178
- NA$144
- FASENRA$119
How this compares
$29,870 in reported general payments places this provider in the 90th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 28 | $355,363 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 330 | $330,222 |
| Dupixent PenDupilumab | 38 | $140,073 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 85 | $76,734 |
| Spiriva RespimatTiotropium Bromide | 83 | $64,543 |
| Breo ElliptaFluticasone/Vilanterol | 86 | $54,503 |
| TezspireTezepelumab-Ekko | 13 | $54,308 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 44 | $29,101 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 51 | $28,524 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $16,111 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $13,339 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 227 | $7,115 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $6,903 |
| EliquisApixaban | 11 | $6,175 |
| Varenicline Tartrate | 18 | $6,086 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $947 | $449,007155 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $19,254 | $424,893501 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $2,283 | $147,153146 claims |
| PfizerEliquis | $37 | $6,17511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Indianapolis
- Gary ZalogaIndianapolis$79K
- Abboud KawakIndianapolis$68K
- George RubeizIndianapolis$24K
- Roberto MachadoIndianapolis$22K
- Rajat NarangIndianapolis$17K
- Michael DuncanIndianapolis$16K
- Marcus TielkerIndianapolis$11K
- Michael SnyderIndianapolis$9K
- Jorge Morales EstrellaIndianapolis$9K
- Cynthia BrownIndianapolis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.